Mobile

A 6-month, double-blind, double-dummy, randomised, parallel group, multicenter, efficacy and safety study of Symbicort® pMDI 2x160/4.5μg and 2x80/4.5μg bid compared to Formoterol Turbuhaler, Budesoni...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-001183-41

A 6-month, double-blind, double-dummy, randomised, parallel group, multicenter, efficacy and safety study of Symbicort® pMDI 2x160/4.5μg and 2x80/4.5μg bid compared to Formoterol Turbuhaler, Budesonide pMDI (& the combination) and Placebo in chronic obstructive pulmonary disease patients (COPD)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare the efficacy (pre-post dose FEV1) of Symbicort® pMDI (pressurised Metered Dose inhaler) 2x 160/4.5μg/inhalation twice daily and of Symbicort® pMDI 2x 80/4.5μg/inhalation twice daily to its mono-products, formoterol Turbuhaler and budesonide pMDI, and placebo, over a 6-month period in patients with COPD.

Critère d'inclusion

  • This is an application for a phase III study to be conducted in COPD patients

Liens